US2017027980A1PendingUtilityA1

Composition based on xyloglucan and proteins for the treatment of intestinal disorders

Assignee: NOVINTETHICAL PHARMA SAPriority: Apr 15, 2014Filed: Apr 15, 2015Published: Feb 2, 2017
Est. expiryApr 15, 2034(~7.7 yrs left)· nominal 20-yr term from priority
A61P 1/00A61P 13/00A61K 38/01A61K 31/716A61K 47/42A61K 36/48A61K 47/36A61K 45/06A61K 9/0078A61K 36/28A61K 31/704A61K 31/732A61K 35/02A61K 31/80A61K 31/733A61K 31/00
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.

Claims

exact text as granted — not AI-modified
1 . Combinations of xyloglucans or extracts containing them and of gelatin for use in the prevention and treatment of diarrhoea, Crohn's disease, ulcerative colitis and irritable bowel syndrome (IBS), diverticulosis, the early stages of diverticulitis, coeliac disease, lactose intolerance, traveller's diarrhoea, cystitis and cystopyelitis. 
     
     
         2 - 3 . (canceled) 
     
     
         4 . Combinations according to  claim 1  wherein the weight ratio between xyloglucan and gelatine is between 1:0.5 and 1:30. 
     
     
         5 . Combinations according to  claim 1  further comprising excipients and/or other active ingredients. 
     
     
         6 . Combinations according to  claim 5  wherein the other active ingredients are selected from antibiotics, antimotility agents, steroidal or non-steroidal anti-inflammatories, compounds for the treatment of gastrointestinal bloating, mesalazine, sucralfate, natural or synthetic polysaccharides, hyaluronic acid, guar gum, xanthan gum, cellulose and hemicellulose, hydroxypropyl cellulose, carrageenans, carbomers, ferulic acid; polyphenols, probiotics and electrolytes.

Join the waitlist — get patent alerts

Track US2017027980A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.